References
- Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
- Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am. 2016;25(3):601–609.
- Lara-Guerra H, Roth JA. Gene therapy for lung cancer. Crit Rev Oncog. 2016;21(1–2):115–124.
- Wang W, Hong G, Wang S, et al. Tumor-derived exosomal miRNA-141 promote angiogenesis and malignant progression of lung cancer by targeting growth arrest-specific homeobox gene (GAX). Bioengineered. 2021;12(1):821–831.
- Zhu N, Wang Z. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells. Cancer Res. 1999;59(8):1896–1902.
- Combes E, Andrade AF, Tosi D, et al. Inhibition of Ataxia-Telangiectasia mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes antitumor immunity in colorectal cancer. Cancer Res. 2019;79(11):2933–2946.
- Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50(5):857–866.
- Fucikova J, Spisek R, Kroemer G, et al. Calreticulin and cancer. Cell Res. 2021;31(1):5–16.
- Lee PC, Chiang JC, Chen CY, et al. Calreticulin regulates vascular endothelial growth factor-A mRNA stability in gastric cancer cells. PloS One. 2019;14(11):e0225107.
- Maheswaran E, Pedersen CB, Ditzel HJ, et al. Lack of ADAM2, CALR3 and SAGE1 cancer/testis antigen expression in lung and breast cancer. PloS One. 2015;10(8):e0134967.
- Stoll G, Iribarren K, Michels J, et al. Calreticulin expression: interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology. 2016;5(7):e1177692.
- Ye T, Jiang K, Wei L, et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J Cancer Res. 2018;8(8):1514–1527.
- Liu X, Li J, Liu Y, et al. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells. Cell Immunol. 2016;300:46–53.
- Dolcet X, Llobet D, Pallares J, et al. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–482.
- Bordoloi D, Banik K, Padmavathi G, et al. TIPE2 induced the proliferation, survival, and migration of lung cancer cells through modulation of akt/mTOR/NF-kappaB signaling cascade. Biomolecules. 2019;9(12):836.
- Basseres DS, Ebbs A, Levantini E, et al. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 2010;70(9):3537–3546.
- Zhou L, Jiang Y, Liu X, et al. Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer. Oncogene. 2019;38(29):5792–5804.
- Chen K, Pan Q, Gao Y, et al. DMS triggers apoptosis associated with the inhibition of SPHK1/NF-kappaB activation and increase in intracellular Ca2+ concentration in human cancer cells. Int J Mol Med. 2014;33(1):17–24.
- Alur M, Nguyen MM, Eggener SE, et al. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009;175(2):882–890.
- Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127(10):1307–1316.
- Fucikova J, Becht E, Iribarren K, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 2016;76(7):1746–1756.
- Garg AD, Elsen S, Krysko DV, et al. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget. 2015;6(29):26841–26860.
- Bergner A, Kellner J, Tufman A, et al. Endoplasmic reticulum Ca2+-homeostasis is altered in small and non-small cell lung cancer cell lines. J Exp Clin Cancer Res. 2009;28(1):25.
- Schrodl K, Oelmez H, Edelmann M, et al. Altered Ca2+-homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells. Cellular oncology: the official journal of the International Society for Cellular Oncology. 2009;31(4):301–315.